Short answer
TANDEM DIABETES CARE INC (TNDM) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $284M (up 13.8% year over year) with net income of −$7M.
Q3 2026 key financials · XBRL
- Revenue
- $284M
- +13.8% YoY · +11.4% QoQ
- Net income
- −$7M
- +66.5% YoY · +66.5% QoQ
- Operating margin
- -0.8%
- Gross margin
- 56.5%
- EPS (diluted)
- −$0.10
- +66.7% YoY · +66.7% QoQ
Source: XBRL data from the TANDEM DIABETES CARE INC (TNDM) Q3 2026 10-Q on SEC EDGAR. USD.
TANDEM DIABETES CARE INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $283.7M, up $34.4M YoY from $249.3M, driven by volumes, pricing and channel mix
- Gross margin 57% vs 54% YoY; operating loss $2.4M vs $22.9M
- Best performer: international supplies and other sales $61.1M vs $48.3M; U.S. pump sales $83.4M vs $84.8M
- Cash and investments $443.1M; operating cash use $24.4M through nine months, financing provided $269.3M
- Headwinds: infusion-set inventory constraints expected through early 2027; pharmacy pay-as-you-go model initially reduces pump sales and gross profit
Risk Factors
- Newly added trade-policy risk: tariff uncertainty affecting Mexico and China imports, with supplier changes potentially requiring costly regulatory resubmissions
- Most material operational update: infusion-set supplier constraints impacting inventory and supply sales, expected to persist through early 2027
- Regulatory and reimbursement risk: CMS finalized competitive bidding and monthly rental payment changes for insulin pumps on December 2, 2025
- Competitive market risk: GLP-1 adoption since 2023 likely reduced demand across the insulin therapy market
- Financial risk: $443.1 million in cash, cash equivalents and short-term investments against $316.3 million 2029 Notes and $300.0 million 2032 Notes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TANDEM DIABETES CARE INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.